The Unique Disclosure Issues and Risks Confronting Biotechs

Thursday, June 13, 2013 (8:00 AM - 9:30 AM)

Date:      Thursday, June 13, 2013          
Time:       8:00 AM  - Registration, Breakfast and Networking  | 8:30-9:30 AM Program  
Price:      No cost to attend!

Barry Kaplan
and Michael Nordtvedt with the law firm of Wilson Sonsini Goodrich & Rosati will discuss "The Unique Disclosure Issues and Risks Confronting Biotechs." All public companies face difficult disclosure issues and are subject to the risk of serious shareholder litigation. For a number of reasons that they will discuss, companies operating in the biotech arena face unique disclosure issues and more pronounced risks. They will explain the difficulties and offer some suggestions for mitigating these risks.

Learning Objectives:

  • Tools to manage inherent scientific, clinical and regulatory uncertainty;
  • Identification of critical disclosure issues;
  • Securities liability landscape; and
  • Practical suggestions for mitigating disclosure risks

Who Should Attend:

  • CEO’s and CFO’s
  • General Counsel
  • Investor relations personnel at public biotech companies and companies contemplating going public

Sponsored by:

© 2012 Washington Biotechnology & Biomedical Association

Powered by